XML 30 R21.htm IDEA: XBRL DOCUMENT
v3.22.2

Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2022
Revenue from Contract with Customer [Abstract] |
Schedule of disaggregation of revenue | The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Net product revenue | $ | 5,870.9 |  |  | $ | 6,070.5 |  |  | $ | 13,003.8 |  |  | $ | 12,390.5 |
Collaboration and other revenue(1) | 617.1 |  |  | 669.6 |  |  | 1,294.2 |  |  | 1,155.2 |
Revenue | $ | 6,488.0 |  |  | $ | 6,740.1 |  |  | $ | 14,298.0 |  |  | $ | 13,545.7 |
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $34.4 million and $87.6 million during the three and six months ended June 30, 2022, respectively, and $31.0 million and $73.9 million during the three and six months ended June 30, 2021, respectively. The following table summarizes revenue by product for the three months ended June 30, 2022 and 2021:
| Three Months Ended June 30,
| 2022 |  | 2021
| U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total
Revenue—to unaffiliated customers: |  |  |  |  |  |  |
Diabetes: |  |  |  |  |  |  |
Trulicity® | $ | 1,430.1 |  | $ | 481.7 |  | $ | 1,911.9 |  |  | $ | 1,147.6 |  | $ | 388.0 |  | $ | 1,535.6 |
Jardiance(1) | 250.7 |  | 210.3 |  | 461.0 |  |  | 194.4 |  | 162.1 |  | 356.5 |
Humalog® (2) | 238.8 |  | 208.3 |  | 447.1 |  |  | 329.1 |  | 278.6 |  | 607.6 |
Humulin® | 202.3 |  | 71.7 |  | 274.0 |  |  | 221.1 |  | 94.3 |  | 315.3 |
Basaglar® | 95.8 |  | 78.4 |  | 174.2 |  |  | 133.4 |  | 77.3 |  | 210.7 |
Other diabetes | 74.5 |  | 95.6 |  | 170.0 |  |  | 54.2 |  | 95.4 |  | 149.8 |
Total diabetes | 2,292.2 |  | 1,146.0 |  | 3,438.2 |  |  | 2,079.8 |  | 1,095.7 |  | 3,175.5 |
Oncology: |  |  |  |  |  |  |
Verzenio® | 384.3 |  | 204.2 |  | 588.5 |  |  | 209.7 |  | 131.6 |  | 341.3 |
Cyramza® | 92.6 |  | 138.6 |  | 231.3 |  |  | 101.4 |  | 167.3 |  | 268.7 |
Alimta® | 171.7 |  | 56.1 |  | 227.7 |  |  | 353.5 |  | 257.1 |  | 610.6 |
Erbitux® | 125.1 |  | 15.7 |  | 140.8 |  |  | 135.8 |  | 11.2 |  | 147.0 |
Tyvyt® | — |  | 73.6 |  | 73.6 |  |  | — |  | 105.0 |  | 105.0 |
Other oncology | 45.3 |  | 61.6 |  | 106.8 |  |  | 27.9 |  | 53.5 |  | 81.4 |
Total oncology | 819.0 |  | 549.8 |  | 1,368.7 |  |  | 828.3 |  | 725.7 |  | 1,554.0 |
Immunology: |  |  |  |  |  |  |
Taltz® | 411.6 |  | 194.7 |  | 606.2 |  |  | 399.8 |  | 169.3 |  | 569.1 |
Olumiant® (3) | 10.4 |  | 175.8 |  | 186.2 |  |  | 17.8 |  | 190.6 |  | 208.4 |
Other immunology | — |  | 4.0 |  | 4.0 |  |  | 4.8 |  | 3.2 |  | 7.9 |
Total immunology | 422.0 |  | 374.5 |  | 796.5 |  |  | 422.4 |  | 363.1 |  | 785.4 |
Neuroscience: |  |  |  |  |  |  |
Emgality® | 108.6 |  | 48.9 |  | 157.5 |  |  | 112.1 |  | 44.2 |  | 156.3 |
Zyprexa® | 8.7 |  | 78.6 |  | 87.3 |  |  | 8.4 |  | 86.9 |  | 95.4 |
Cymbalta® | 8.1 |  | 67.4 |  | 75.5 |  |  | 12.4 |  | 163.3 |  | 175.6 |
Other neuroscience | 19.4 |  | 50.3 |  | 69.6 |  |  | 33.8 |  | 51.1 |  | 84.9 |
Total neuroscience | 144.8 |  | 245.2 |  | 389.9 |  |  | 166.7 |  | 345.5 |  | 512.2 |
Other: |  |  |  |  |  |  |
Cialis® | 10.8 |  | 136.2 |  | 147.0 |  |  | (5.2) |  | 286.3 |  | 281.0 |
Forteo® | 78.5 |  | 60.0 |  | 138.5 |  |  | 122.8 |  | 95.6 |  | 218.4 |
COVID-19 antibodies(4) | 129.1 |  | — |  | 129.1 |  |  | 83.4 |  | 65.7 |  | 148.9 |
Other | 38.5 |  | 41.7 |  | 80.1 |  |  | 6.0 |  | 58.4 |  | 64.6 |
Total other | 256.9 |  | 237.9 |  | 494.7 |  |  | 207.0 |  | 506.0 |  | 712.9 |
Revenue | $ | 3,934.8 |  | $ | 2,553.3 |  | $ | 6,488.0 |  |  | $ | 3,704.2 |  | $ | 3,035.9 |  | $ | 6,740.1 |
Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR. (2) Humalog revenue includes insulin lispro. (3) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations. (4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. The following table summarizes revenue by product for the six months ended June 30, 2022 and 2021:
| Six Months Ended June 30,
| 2022 |  | 2021
| U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total
Revenue—to unaffiliated customers: |  |  |  |  |  |  |
Diabetes: |  |  |  |  |  |  |
Trulicity | $ | 2,744.1 |  | $ | 909.1 |  | $ | 3,653.2 |  |  | $ | 2,264.3 |  | $ | 723.7 |  | $ | 2,988.1 |
Humalog(1) | 607.7 |  | 457.6 |  | 1,065.3 |  |  | 661.7 |  | 562.9 |  | 1,224.6 |
Jardiance(2) | 480.4 |  | 400.0 |  | 880.4 |  |  | 345.6 |  | 322.9 |  | 668.5 |
Humulin | 392.8 |  | 154.5 |  | 547.2 |  |  | 440.1 |  | 196.9 |  | 637.0 |
Basaglar | 215.1 |  | 150.6 |  | 365.7 |  |  | 308.6 |  | 148.7 |  | 457.3 |
Other diabetes | 128.6 |  | 185.8 |  | 314.5 |  |  | 120.7 |  | 190.4 |  | 311.1 |
Total diabetes | 4,568.7 |  | 2,257.6 |  | 6,826.3 |  |  | 4,141.0 |  | 2,145.5 |  | 6,286.6 |
Oncology: |  |  |  |  |  |  |
Verzenio | 685.7 |  | 372.1 |  | 1,057.9 |  |  | 382.5 |  | 227.8 |  | 610.3 |
Alimta | 425.9 |  | 145.8 |  | 571.7 |  |  | 614.6 |  | 554.9 |  | 1,169.6 |
Cyramza | 171.8 |  | 289.7 |  | 461.5 |  |  | 181.5 |  | 327.7 |  | 509.2 |
Erbitux | 234.7 |  | 28.7 |  | 263.4 |  |  | 243.7 |  | 25.7 |  | 269.4 |
Tyvyt | — |  | 159.0 |  | 159.0 |  |  | — |  | 214.6 |  | 214.6 |
Other oncology | 84.6 |  | 123.7 |  | 208.2 |  |  | 48.5 |  | 104.7 |  | 153.2 |
Total oncology | 1,602.7 |  | 1,119.0 |  | 2,721.7 |  |  | 1,470.8 |  | 1,455.4 |  | 2,926.3 |
Immunology: |  |  |  |  |  |  |
Taltz | 718.8 |  | 375.5 |  | 1,094.3 |  |  | 649.4 |  | 322.9 |  | 972.4 |
Olumiant(3) | 81.7 |  | 360.1 |  | 441.8 |  |  | 42.5 |  | 359.7 |  | 402.2 |
Other immunology | — |  | 8.5 |  | 8.5 |  |  | 15.2 |  | 9.6 |  | 24.7 |
Total immunology | 800.5 |  | 744.1 |  | 1,544.6 |  |  | 707.1 |  | 692.2 |  | 1,399.3 |
Neuroscience: |  |  |  |  |  |  |
Emgality | 216.9 |  | 89.8 |  | 306.7 |  |  | 213.6 |  | 62.2 |  | 275.7 |
Zyprexa | 18.3 |  | 162.1 |  | 180.4 |  |  | 15.3 |  | 175.8 |  | 191.1 |
Cymbalta | 17.2 |  | 139.4 |  | 156.6 |  |  | 23.3 |  | 328.9 |  | 352.3 |
Other neuroscience | 45.7 |  | 98.2 |  | 144.0 |  |  | 56.2 |  | 102.3 |  | 158.5 |
Total neuroscience | 298.1 |  | 489.5 |  | 787.7 |  |  | 308.4 |  | 669.2 |  | 977.6 |
Other: |  |  |  |  |  |  |
COVID-19 antibodies(4) | 1,584.3 |  | 14.7 |  | 1,598.9 |  |  | 734.0 |  | 225.1 |  | 959.1 |
Cialis | 17.7 |  | 347.0 |  | 364.7 |  |  | 3.4 |  | 404.4 |  | 407.8 |
Forteo | 148.7 |  | 127.2 |  | 275.9 |  |  | 220.5 |  | 196.4 |  | 416.9 |
Other | 88.5 |  | 89.6 |  | 178.2 |  |  | 60.2 |  | 111.9 |  | 172.1 |
Total other | 1,839.2 |  | 578.5 |  | 2,417.7 |  |  | 1,018.1 |  | 937.8 |  | 1,955.9 |
Revenue | $ | 9,109.4 |  | $ | 5,188.7 |  | $ | 14,298.0 |  |  | $ | 7,645.5 |  | $ | 5,900.2 |  | $ | 13,545.7 |
Numbers may not add due to rounding. (1) Humalog revenue includes insulin lispro. (2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (3) Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations. (4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. The following table summarizes revenue by geographical area:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue—to unaffiliated customers(1): |  |  |  |  |  |  |
U.S. | $ | 3,934.8 |  |  | $ | 3,704.2 |  |  | $ | 9,109.4 |  |  | $ | 7,645.5 |
Europe | 1,101.1 |  |  | 1,209.8 |  |  | 2,168.4 |  |  | 2,531.0 |
Japan | 454.4 |  |  | 665.4 |  |  | 864.6 |  |  | 1,237.2 |
China | 352.1 |  |  | 522.5 |  |  | 758.5 |  |  | 884.7 |
Other foreign countries | 645.7 |  |  | 638.1 |  |  | 1,397.2 |  |  | 1,247.3 |
Revenue | $ | 6,488.0 |  |  | $ | 6,740.1 |  |  | $ | 14,298.0 |  |  | $ | 13,545.7 |
Numbers may not add due to rounding. (1) Revenue is attributed to the countries based on the location of the customer.
Schedule of amounts recorded for contract liabilities | The following table summarizes contract liability balances:
| June 30, 2022 |  | December 31, 2021
Contract liabilities | $ | 242.1 |  |  | $ | 262.6 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration